Previous 10 | Next 10 |
home / stock / ipsef / ipsef news
Ipsen S.A. (IPSEY) Q4 2021 Earnings Conference Call February 11, 2022, 8:00 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Group Chief Financial Officer Howard Mayer – Head of Research and Development Conference Call Participants Je...
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
Meme-stock favorite AMC (NYSE:AMC) returned to the headlines during Friday's midday trading, posting a double-digit percentage gain on strong early box office totals for the new Spider-Man movie. Elsewhere in the market, drug development news prompted notable gains in Novavax (NASDAQ:NVAX) an...
The following slide deck was published by Ipsen S.A. in conjunction with this event. For further details see: Ipsen S.A. (IPSEY) Investor Presentation - Slideshow
Mirati Therapeutics (MRTX +4.9%) has reached a four-month high amid a series of catalysts, including the appointment of the industry veteran David Meek as the new CEO. Mr. Meek will assume duties as the CEO and will join the company board effective immediately, Mirati (NASDAQ:MRTX) said ...
Ipsen (OTCPK:IPSEY) and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome. Under the agreement, Ipsen will rec...
Ipsen S.A. (IPSEY) Q2 2021 Earnings Conference Call July 29, 2021 08:30 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - EVP and Group CFO Conference Call Participants Elizabeth Walton - Credit Suisse Sachin Jain, Bank - America Delphine Le Louet - Societe Generale Rosie Tur...
The following slide deck was published by Ipsen S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Ipsen S.A. 2021 Q1 - Results - Earnings Call Presentation
Sohel_Parvez_Haque/iStock via Getty Images Exelixis, (EXEL) down 6% premarket and Ipsen (IPSEY) announce that Phase 3 COSMIC-312 trial evaluating cabozantinib (Cabometyx) in combination with Roche's (RHHBY) atezolizumab vs. sorafenib in patients with previously untreated advanced he...
Ipsen (IPSEY) to buyback 500K shares, or about 0.6% of the share capital, over a maximum period of six months.The shares purchased under this agreement will be allocated mainly to cover its free performance share-allocation plans and its new employee share-ownership plan. For further detail...
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified throug...
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...